Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines.

@article{Hallek2008GuidelinesFT,
  title={Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines.},
  author={Michael Hallek and Bruce D Cheson and Daniel Catovsky and Federico caligaris-Cappio and Guillaume Dighiero and Hartmut D{\"o}hner and Peter Hillmen and Michael J. Keating and Emili Montserrat and Kanti R. Rai and Thomas J. Kipps},
  journal={Blood},
  year={2008},
  volume={111 12},
  pages={
          5446-56
        }
}
Standardized criteria for diagnosis and response assessment are needed to interpret and compare clinical trials and for approval of new therapeutic agents by regulatory agencies. Therefore, a National Cancer Institute-sponsored Working Group (NCI-WG) on chronic lymphocytic leukemia (CLL) published guidelines for the design and conduct of clinical trials for patients with CLL in 1988, which were updated in 1996. During the past decade, considerable progress has been achieved in defining new… 

Tables from this paper

Changes in the incidence, pattern of presentation and clinical outcome of early chronic lymphocytic leukemia patients using the 2008 International Workshop on CLL guidelines
TLDR
The 2008 IWCLL guidelines modify the distribution of Rai stage at diagnosis and shorten the time to first treatment in early CLL patients, which are expected to be considered in the interpretation of epidemiologic studies in CLL and in designing clinical trials of early therapeutic intervention in patients with asymptomatic CLL.
Guidelines for Diagnosis, Indications for Treatment, Response Assessment, and Supportive Management of Chronic Lymphocytic Leukemia: The 2018 Update
TLDR
These guidelines were recently published and include a revised version of the iwCLL response criteria, an update on the use of the MRD status in the clinical context, and recommendations regarding the assessment and prophylaxis of viral diseases during the management of CLL.
Prognostic factors in chronic lymphocytic leukemia.
  • M. Hallek
  • Medicine, Biology
    Annals of oncology : official journal of the European Society for Medical Oncology
  • 2008
TLDR
The current evidence with regard to novel biological markers in CLL is summarized and the recommendations of the recently revised National Cancer Institute guidelines for the diagnosis and treatment of CLL will be incorporated.
Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia.
  • B. Cheson, J. Byrd, T. Kipps
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2012
Standardized criteria for response to therapy in patients with chronic lymphocytic leukemia (CLL), lymphoma, and other malignancies allow for comparisons of outcome between clinical trials and have
Clinical Evaluation and Management of Chronic Lymphocytic Leukemia
TLDR
The role of chemotherapy for patients with CLL has declined and several novel targeted therapy agents have been developed targeting CLL cells, including ibrutinib, idelalisib, and venetoclax.
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL.
TLDR
Recommendations include a revised version of the iwCLL response criteria, an update on the use of MRD status for clinical evaluation, and recommendations regarding the assessment and prophylaxis of viral diseases during management of CLL.
Differentiating chronic lymphocytic leukemia from monoclonal B-lymphocytosis according to clinical outcome: on behalf of the GIMEMA chronic lymphoproliferative diseases working group
TLDR
The results, based on a retrospective patients’ cohort, provide a clear justification to retain the B-cell count as the reference gold standard of chronic lymphocytic leukemia diagnosis and imply that a count of 10×109/L B cells is the best lymphocyte threshold to predict time to first treatment.
Canadian evidence-based guideline for the first-line treatment of chronic lymphocytic leukemia.
TLDR
A group of clinical experts from across Canada developed a national evidence-based treatment guideline to provide health care professionals with clear guidance on the first-line management of chronic lymphocytic leukemia.
Chronic lymphocytic leukemia and focusing on epidemiology and management in everyday hematologic practice: recent data from the Czech Leukemia Study Group for Life (CELL).
TLDR
The ascertained incidence of CLL in the South Moravian Region is higher than declared incidence in the past, indicating that CLL became an often misdiagnosed and underreported disease.
...
...

References

SHOWING 1-10 OF 112 REFERENCES
Guidelines for clinical protocols for chronic lymphocytic leukemia: Recommendations of the national cancer institute‐sponsored working group
TLDR
The National Cancer Institute‐sponsored Chronic Lymphocytic Leukemia (CLL) Working Group was convened to develop a set of standardized eligibility, response, and toxicity criteria for clinical trials, and the emergence of several chemotherapy agents that promise impressive activity in CLL is witnessed.
Computed tomography scans do not improve the predictive power of 1996 national cancer institute sponsored working group chronic lymphocytic leukemia response criteria.
  • K. Blum, D. Young, J. Byrd
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2007
TLDR
Current NCI-WG CLL response criteria are a significant predictor of PFS in previously treated CLL patients, with no additional benefit from the inclusion of CT scans, although retrospective results highlight the importance of prospective validation ofCT scans before routine inclusion in CLL responded criteria.
Prospective Evaluation of Prognostic Parameters in Early Stage Chronic Lymphocytic Leukemia (CLL): Results of the CLL1-Protocol of the German CLL Study Group (GCLLSG).
TLDR
This prospective trial defined clinical and biological factors (TK, LDT, beta-2-MG, absolute lymphocyte count, age, sex) which help to predict progression in early CLL and its model for risk stratification reliably separated between HR and LR.
Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia.
TLDR
A weighted prognostic model, or nomogram, predictive for overall survival was constructed using the following independent characteristics: age, beta-2 microglobulin, absolute lymphocyte count, sex, Rai stage, and number of involved lymph node groups to help patients and clinicians in clinical decision making as well as in clinical research and clinical trial design.
Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia.
TLDR
The data suggest that the fundamental biologic issue is whether a clonal population is present in monoclonal B-cell lymphocytosis and early chronic lymphocytic leukemia and if an MBL clone with the CLL phenotype is present, there appears to be a risk of progression, and the absolute level of the clone is a secondary consideration.
Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival.
  • P. Moreton, B. Kennedy, P. Hillmen
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2005
TLDR
MRD-negative remission in CLL is achievable with alemtuzumab, leading to an improved overall and treatment-free survival.
Tumor lysis syndrome: an uncommon complication of fludarabine therapy of chronic lymphocytic leukemia.
TLDR
TLS after fludarabine therapy is extremely uncommon, but may be associated with significant morbidity and mortality.
Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus
The aim of this project was to identify situations where allogeneic stem cell transplantation (allo-SCT) might be considered as a preferred treatment option for patients with B-cell chronic
Chemotherapeutic Options in Chronic Lymphocytic Leukemia: a Meta-analysis of the Randomized Trials
TLDR
These trials support a conservative treatment strategy for CLL, and single-agent chlorambucil as the first line of treatment for most patients with advanced disease, with no evidence of benefit from early inclusion of an anthracycline.
Updated guidelines on the management of cytomegalovirus reactivation in patients with chronic lymphocytic leukemia treated with alemtuzumab.
TLDR
Several strategies for monitoring and treating CMV reactivation in patients with CLL receiving alemtuzumab-based therapy are discussed and practical recommendations for CMV management are provided by building upon the guidelines published previously in 2004.
...
...